ArticleFrontiers in oncology2020
Cone-Beam-CT Guided Adaptive Radiotherapy for Locally Advanced Non-small Cell Lung Cancer Enables Quality Assurance and Superior Sparing of Healthy Lung.
Article in Frontiers in oncology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 2 syntheses or guidelines pooled it, 31 citations in OpenAlex.
- Efficacy and safety of stereotactic radiosurgery versus whole brain radiotherapy for the treatment of brain metastasis: a systematic review and meta-analysis.Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology · 2025Pooled it
- Deep learning methods for enhancing cone-beam CT image quality toward adaptive radiation therapy: A systematic review.Medical physics · 2022Pooled it
- Evaluation of online dose-guided adaptive fractionation for intact prostate radiotherapy.Journal of applied clinical medical physics · 2026Article
- Does the traffic light protocol capture dose deviations? A longitudinal CBCT-based dose-monitoring study in adaptive RT for LA-NSCLC.Technical innovations & patient support in radiation oncology · 2026Article
- Key technologies and challenges in online adaptive radiotherapy for lung cancer.Chinese medical journal · 2025Review
- Adaptive treatment margins to reduce organs at risk dose in patients with no or minimal anatomical changes in radiotherapy of non-small cell lung cancer.Physics and imaging in radiation oncology · 2025Article
- Article
- Progressive auto-segmentation for cone-beam computed tomography-based online adaptive radiotherapy.Physics and imaging in radiation oncology · 2024Article
- Factors that Influence the Need to Start Adaptive Radiotherapy.Journal of immunotherapy and precision oncology · 2024Article
- Comparison of different dose accumulation strategies to estimate organ doses after stereotactic magnetic resonance-guided adaptive radiotherapy.Radiation oncology (London, England) · 2023Article
- Pulmonary magnetic resonance-guided online adaptive radiotherapy of locally advanced: the PUMA trial.Radiation oncology (London, England) · 2023Article
- Stereotactic magnetic resonance-guided online adaptive radiotherapy of adrenal metastases combines high ablative doses with optimized sparing of organs at risk.Clinical and translational radiation oncology · 2023Article
- Dosimetric benefits of adaptive radiation therapy for patients with stage III non-small cell lung cancer.Radiation oncology (London, England) · 2023Article
- PET/CT-based adaptive radiotherapy of locally advanced non-small cell lung cancer in multicenter yDEGRO ARO 2017-01 cohort study.Radiation oncology (London, England) · 2022Observational
- Magnetic resonance linear accelerator technology and adaptive radiation therapy: An overview for clinicians.CA: a cancer journal for clinicians · 2022Review
- Machine-learning-based prediction of the effectiveness of the delivered dose by exhale-gated radiotherapy for locally advanced lung cancer: The additional value of geometric over dosimetric parameters alone.Frontiers in oncology · 2022Article
- Online Adaptive Radiation Therapy and Opportunity Cost.Advances in radiation oncologyArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors at 6 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeTo evaluate the potential of cone-beam-CT (CB-CT) guided adaptive radiotherapy (ART) for locally advanced non-small cell lung cancer (NSCLC) for sparing of surrounding organs-at-risk (OAR). MATERIALS AND
methodsIn 10 patients with locally advanced NSCLC, daily CB-CT imaging was acquired during radio- (n = 4) or radiochemotherapy (n = 6) for simulation of ART. Patients were treated with conventionally fractionated intensity-modulated radiotherapy (IMRT) with total doses of 60-66 Gy (pPlan) (311 fraction CB-CTs). OAR were segmented on every daily CB-CT and the tumor volumes were modified weekly depending on tumor changes. Doses actually delivered were recalculated on daily images (dPlan), and voxel-wise dose accumulation was performed using a deformable registration algorithm. For simulation of ART, treatment plans were adapted using the new contours and re-optimized weekly (aPlan).
resultsCB-CT showed continuous tumor regression of 1.1 ± 0.4% per day, leading to a residual gross tumor volume (GTV) of 65.3 ± 13.4% after 6 weeks of radiotherapy (p = 0.005). Corresponding PTVs decreased to 83.7 ± 7.8% (p = 0.005). In the actually delivered plans (dPlan), both conformity (p = 0.005) and homogeneity (p = 0.059) indices were impaired compared to the initial plans (pPlan). This resulted in higher actual lung doses than planned: V
conclusionIGRT with CB-CT detects continuous GTV and PTV changes. CB-CT-guided ART for locally advanced NSCLC is feasible and enables superior sparing of healthy lung at high levels of plan conformity.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.